Myriad Genetics (MYGN) Income Statement

Click line-items for a historical chart and %

Consolidated Statements Of Income
Molecular diagnostic testing	165.1M
Companion diagnostic services	12.4M
Total revenue	177.5M
Costs and expenses:
Cost of molecular diagnostic testing	34.3M
Cost of companion diagnostic services
Research and development expense	19.4M
Selling, general, and administrative expense	111.9M
Total costs and expenses	171.3M
Operating income	6.2M
Other income (expense):
Interest income	300K
Other
Total other income
Income from continuing operations before income taxes	4M
Income tax provision (benefit)	5.2M
Income from continuing operations
Discontinued operations (Note 15)
Loss from discontinued operations
Net income	-1.2M
Earnings (loss) per basic share
Continuing operations
Discontinued operations
Earnings per basic share	-0.02
Earnings (loss) per diluted share
Continuing operations
Discontinued operations
Earnings per diluted share	-0.02
Weighted average shares outstanding
Basic	68.8M
Diluted	68.8M

Entities mentioned with MYGN